Business Wire

CA-SENTRY

4.5.2022 15:02:13 CEST | Business Wire | Press release

Share
Sentry Raises $90 Million in Series E Funding to Expand and Drive Adoption of Developer-first Application Monitoring

Sentry , the market leader in developer-first application monitoring, today announced it has raised $90 million for its Series E, bringing the company’s total funding to $217 million and valuing the company at more than $3 billion. This round was co-led by BOND and Accel , with participation from existing investor New Enterprise Associates (NEA) and new investor K5 Global . The new capital will help fuel the company’s long-term growth for product development, hiring, and global expansion in Europe.

Sentry is reshaping application performance monitoring (APM) by directly addressing the developer experience gap. With the proliferation of applications, languages, and frameworks, Sentry empowers any developer or development team to solve issues in production code by using one tool to monitor for errors, performance, and health across mobile, desktop, and IoT, and across any industry or vertical.

In the past year, the company saw rapid growth driven by customer adoption of Error and Performance Monitoring, with net expansion of annual recurring revenue (ARR) increasing by 130%+ year over year. Sentry now processes 790+ billion events per month, with mobile events increasing by more than 100% year over year.

“Our singular focus on developers, combined with the depth of our platform across 100+ languages, allows us to uniquely solve developer problems for every customer and software environment,” said Milin Desai, CEO at Sentry. “Revenue has more than tripled in just over two years, and our team will continue to be laser-focused on providing engineering organizations with the ability to ship better code faster.”

"Our customers expect constant improvements to the product experience along with new feature updates, and without any disruptions to their current workflows,” said Kah Seng Tay, GM and Head of Cloud and Developer Infrastructure at Airtable . “With Sentry providing accurate and diagnosable alerts, we’re able to better triage incidents during deployment and decentralize our release process. This all results in our engineering teams being able to ship code more efficiently and more frequently, while still keeping the quality of our service high."

“We ship a tremendous amount of code — eight deployments at the top of every hour — to launch new features. Combined with a highly distributed architecture, it was getting more and more complex for our teams to identify and fix errors and performance issues,” said Eviathar Moussaffi, Group Lead of Engineering at monday.com . “Providing the most optimal user experience to our customers is critical to the success of our business, and Sentry allows us to eliminate unnecessary noise and reduces the time to resolution, so our developers can be most effective. The demands on our business are only going to increase, and Sentry provides a way for our team to have a holistic view of the health of our applications.”

“The rate at which businesses are moving towards a digital-first mindset is unprecedented,” said Jay Simons , General Partner at BOND. “In order to sustain applications, programs, and mobile, the proper infrastructure needs to be in place to manage and monitor the health of every customer solution. For many businesses, an error in code or a performance issue in the final touchpoint with an end-user can mean the loss of a sale or customer.”

“The rate of software development is going to exponentially increase, and developers are seeking ways to quickly solve any issues that will affect the end-user experience,” said Dan Levine , Partner at Accel, a firm that has also invested in companies like Atlassian, CrowdStrike, Dropbox, PagerDuty, Qualtrics, and Slack. “With Sentry, companies can not only pinpoint the exact issue but also proactively monitor their application health. As we continue to see the move towards a digital-first world, Sentry is well-positioned to help companies, from small businesses to enterprises, ensure that they’re keeping up with customer expectations.”

To support growing demand, Sentry’s team has grown nearly 75% worldwide since this time last year, with plans to continue hiring for all offices, including a new hub opening in Europe. With this round of funding, Sentry will accelerate its go-to-market motion and teams, as the company expands on its product-led growth model and servicing its global customer base.

Learn more about Sentry’s plans for innovation and growth on the company blog .

About Sentry

For software teams, Sentry is essential for monitoring code health. From Error tracking to Performance Monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Peloton, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub , Twitter , Dribbble or LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an

Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release

Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye